Search

Your search keyword '"Caskey, Marina"' showing total 480 results
Start Over Author "Caskey, Marina"
480 results on '"Caskey, Marina"'

1. Safety, Efficacy, and Pharmacokinetics of Combination SARS-CoV-2 Neutralizing Monoclonal Antibodies BMS-986414 (C135-LS) and BMS-986413 (C144-LS) Administered Subcutaneously in Non-Hospitalized Persons with COVID-19 in a Phase 2 Trial

Author

Corado, Katya C, Chew, Kara W, Giganti, Mark J, Mu, Ying, Fletcher, Courtney V, Currier, Judith S, Daar, Eric S, Wohl, David A, Li, Jonathan Z, Moser, Carlee B, Ritz, Justin, Javan, Arzhang Cyrus, Neytman, Gene, Caskey, Marina, Hughes, Michael D, Smith, Davey M, Eron, Joseph J, and Team, ACTIV-2 A5401 Study

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Emerging Infectious Diseases, Coronaviruses, Coronaviruses Therapeutics and Interventions, Infectious Diseases, Clinical Trials and Supportive Activities, Immunization, Biotechnology, Clinical Research, 6.1 Pharmaceuticals, ACTIV-2/A5401 Study Team, COVID-19, SARS-CoV-2, monoclonal antibodies, outpatient treatment, subcutaneous, Clinical sciences, Immunology, Medical microbiology
Abstract

BackgroundOutpatient COVID-19 monoclonal antibody (mAb) treatment via subcutaneous delivery, if effective, overcomes the logistical burdens of intravenous administration.MethodsACTIV-2/A5401 was a randomized, masked placebo-controlled platform trial where participants with COVID-19 at low risk for progression were randomized 1:1 to subcutaneously administered BMS-986414 (C135-LS) 200 mg, plus BMS-986413 (C144-LS) 200 mg, (BMS mAbs), or placebo. Coprimary outcomes were time to symptom improvement through 28 days; nasopharyngeal SARS-CoV-2 RNA below the lower limit of quantification (LLoQ) on days 3, 7, or 14; and treatment-emergent grade 3 or higher adverse events (TEAEs) through 28 days.ResultsA total of 211 participants (105 BMS mAbs and 106 placebo) initiated study product. Time to symptom improvement favored the active therapy but was not significant (median 8 vs 10 days, P=0.19). There was no significant difference in the proportion with SARS-CoV-2 RNA ConclusionsWhile safe, the BMS mAbs delivered subcutaneously were not effective at treating COVID-19 at low risk for progression. The lack of clinically significant activity may relate to the pharmacokinetics of subcutaneous administration of mAbs.

Published
2024

2. Impact of a TLR9 agonist and broadly neutralizing antibodies on HIV-1 persistence: the randomized phase 2a TITAN trial

Author

Gunst, Jesper D., Højen, Jesper F., Pahus, Marie H., Rosás-Umbert, Miriam, Stiksrud, Birgitte, McMahon, James H., Denton, Paul W., Nielsen, Henrik, Johansen, Isik S., Benfield, Thomas, Leth, Steffen, Gerstoft, Jan, Østergaard, Lars, Schleimann, Mariane H., Olesen, Rikke, Støvring, Henrik, Vibholm, Line, Weis, Nina, Dyrhol-Riise, Anne M., Pedersen, Karen B. H., Lau, Jillian S. Y., Copertino, Jr, Dennis C., Linden, Noemi, Huynh, Tan T., Ramos, Victor, Jones, R. Brad, Lewin, Sharon R., Tolstrup, Martin, Rasmussen, Thomas A., Nussenzweig, Michel C., Caskey, Marina, Reikvam, Dag Henrik, and Søgaard, Ole S.

Published
2023
Full Text
View/download PDF

5. Detection and characterization of the SARS-CoV-2 lineage B.1.526 in New York

Author

West, Anthony P, Wertheim, Joel O, Wang, Jade C, Vasylyeva, Tetyana I, Havens, Jennifer L, Chowdhury, Moinuddin A, Gonzalez, Edimarlyn, Fang, Courtney E, Di Lonardo, Steve S, Hughes, Scott, Rakeman, Jennifer L, Lee, Henry H, Barnes, Christopher O, Gnanapragasam, Priyanthi NP, Yang, Zhi, Gaebler, Christian, Caskey, Marina, Nussenzweig, Michel C, Keeffe, Jennifer R, and Bjorkman, Pamela J

Subjects
Biological Sciences, Bioinformatics and Computational Biology, Genetics, Coronaviruses, Infectious Diseases, Human Genome, Emerging Infectious Diseases, Good Health and Well Being
Abstract

Wide-scale SARS-CoV-2 genome sequencing is critical to tracking viral evolution during the ongoing pandemic. Variants first detected in the United Kingdom, South Africa, and Brazil have spread to multiple countries. We developed the software tool, Variant Database (VDB), for quickly examining the changing landscape of spike mutations. Using VDB, we detected an emerging lineage of SARS-CoV-2 in the New York region that shares mutations with previously reported variants. The most common sets of spike mutations in this lineage (now designated as B.1.526) are L5F, T95I, D253G, E484K or S477N, D614G, and A701V. This lineage was first sequenced in late November 2020 when it represented

Published
2021

6. Safety, tolerability, pharmacokinetics, and immunological activity of dual-combinations and triple-combinations of anti-HIV monoclonal antibodies PGT121, PGDM1400, 10-1074, and VRC07-523LS administered intravenously to HIV-uninfected adults: a phase 1 randomised trial

Author

Sobieszczyk, Magdalena E, Mannheimer, Sharon, Paez, Carmen A, Yu, Chenchen, Gamble, Theresa, Theodore, Deborah A, Chege, Wairimu, Yacovone, Margaret, Hanscom, Brett, Heptinstall, Jack, Seaton, Kelly E, Zhang, Lily, Miner, Maurine D, Eaton, Amanda, Weiner, Joshua A, Mayer, Kenneth, Kalams, Spyros, Stephenson, Kathryn, Julg, Boris, Caskey, Marina, Nussenzweig, Michel, Gama, Lucio, Barouch, Dan H, Ackerman, Margaret E, Tomaras, Georgia D, Huang, Yunda, and Montefiori, David

Published
2023
Full Text
View/download PDF

7. ReScan, a Multiplex Diagnostic Pipeline, Pans Human Sera for SARS-CoV-2 Antigens

Author

Zamecnik, Colin R, Rajan, Jayant V, Yamauchi, Kevin A, Mann, Sabrina A, Loudermilk, Rita P, Sowa, Gavin M, Zorn, Kelsey C, Alvarenga, Bonny D, Gaebler, Christian, Caskey, Marina, Stone, Mars, Norris, Philip J, Gu, Wei, Chiu, Charles Y, Ng, Dianna, Byrnes, James R, Zhou, Xin X, Wells, James A, Robbiani, Davide F, Nussenzweig, Michel C, DeRisi, Joseph L, and Wilson, Michael R

Subjects
Biomedical and Clinical Sciences, Immunization, Vaccine Related, Emerging Infectious Diseases, Coronaviruses, Infectious Diseases, Clinical Research, Biotechnology, 4.1 Discovery and preclinical testing of markers and technologies, Good Health and Well Being, Antibodies, Viral, Antigens, Viral, COVID-19, COVID-19 Serological Testing, Female, Humans, Male, Middle Aged, Peptide Library, Protein Array Analysis, Proteome, Reproducibility of Results, SARS-CoV-2, Sensitivity and Specificity, Viral Proteins, assay development, diagnostics, phage display, serology, Biomedical and clinical sciences
Abstract

Comprehensive understanding of the serological response to SARS-CoV-2 infection is important for both pathophysiologic insight and diagnostic development. Here, we generate a pan-human coronavirus programmable phage display assay to perform proteome-wide profiling of coronavirus antigens enriched by 98 COVID-19 patient sera. Next, we use ReScan, a method to efficiently sequester phage expressing the most immunogenic peptides and print them onto paper-based microarrays using acoustic liquid handling, which isolates and identifies nine candidate antigens, eight of which are derived from the two proteins used for SARS-CoV-2 serologic assays: spike and nucleocapsid proteins. After deployment in a high-throughput assay amenable to clinical lab settings, these antigens show improved specificity over a whole protein panel. This proof-of-concept study demonstrates that ReScan will have broad applicability for other emerging infectious diseases or autoimmune diseases that lack a valid biomarker, enabling a seamless pipeline from antigen discovery to diagnostic using one recombinant protein source.

Published
2020

8. Recommendations for measuring HIV reservoir size in cure-directed clinical trials.

Author

Abdel-Mohsen, Mohamed, Richman, Douglas, Siliciano, Robert F, Nussenzweig, Michel C, Howell, Bonnie J, Martinez-Picado, Javier, Chomont, Nicolas, Bar, Katharine J, Yu, Xu G, Lichterfeld, Mathias, Alcami, Jose, Hazuda, Daria, Bushman, Frederic, Siliciano, Janet D, Betts, Michael R, Spivak, Adam M, Planelles, Vicente, Hahn, Beatrice H, Smith, Davey M, Ho, Ya-Chi, Buzon, Maria J, Gaebler, Christian, Paiardini, Mirko, Li, Qingsheng, Estes, Jacob D, Hope, Thomas J, Kostman, Jay, Mounzer, Karam, Caskey, Marina, Fox, Lawrence, Frank, Ian, Riley, James L, Tebas, Pablo, Montaner, Luis J, and BEAT-HIV Delaney Collaboratory to Cure HIV-1 infection

Subjects
BEAT-HIV Delaney Collaboratory to Cure HIV-1 infection, Medical and Health Sciences, Immunology
Abstract

Therapeutic strategies are being clinically tested either to eradicate latent HIV reservoirs or to achieve virologic control in the absence of antiretroviral therapy. Attaining this goal will require a consensus on how best to measure the numbers of persistently infected cells with the potential to cause viral rebound after antiretroviral-therapy cessation in assessing the results of cure-directed strategies in vivo. Current measurements assess various aspects of the HIV provirus and its functionality and produce divergent results. Here, we provide recommendations from the BEAT-HIV Martin Delaney Collaboratory on which viral measurements should be prioritized in HIV-cure-directed clinical trials.

Published
2020

9. Antibody feedback regulates immune memory after SARS-CoV-2 mRNA vaccination

Author

Schaefer-Babajew, Dennis, Wang, Zijun, Muecksch, Frauke, Cho, Alice, Loewe, Maximilian, Cipolla, Melissa, Raspe, Raphael, Johnson, Brianna, Canis, Marie, DaSilva, Justin, Ramos, Victor, Turroja, Martina, Millard, Katrina G., Schmidt, Fabian, Witte, Leander, Dizon, Juan, Shimeliovich, Irina, Yao, Kai-Hui, Oliveira, Thiago Y., Gazumyan, Anna, Gaebler, Christian, Bieniasz, Paul D., Hatziioannou, Theodora, Caskey, Marina, and Nussenzweig, Michel C.

Published
2023
Full Text
View/download PDF

10. Early intervention with 3BNC117 and romidepsin at antiretroviral treatment initiation in people with HIV-1: a phase 1b/2a, randomized trial

Author

Gunst, Jesper D., Pahus, Marie H., Rosás-Umbert, Miriam, Lu, I-Na, Benfield, Thomas, Nielsen, Henrik, Johansen, Isik S., Mohey, Rajesh, Østergaard, Lars, Klastrup, Vibeke, Khan, Maryam, Schleimann, Mariane H., Olesen, Rikke, Støvring, Henrik, Denton, Paul W., Kinloch, Natalie N., Copertino, Dennis C., Ward, Adam R., Alberto, Winiffer D. Conce, Nielsen, Silke D., Puertas, Maria C., Ramos, Victor, Reeves, Jacqueline D., Petropoulos, Christos J., Martinez-Picado, Javier, Brumme, Zabrina L., Jones, R. Brad, Fox, Julie, Tolstrup, Martin, Nussenzweig, Michel C., Caskey, Marina, Fidler, Sarah, and Søgaard, Ole S.

Published
2022
Full Text
View/download PDF

12. Recommendations for analytical antiretroviral treatment interruptions in HIV research trials—report of a consensus meeting

Author

Julg, Boris, Dee, Lynda, Ananworanich, Jintanat, Barouch, Dan H, Bar, Katharine, Caskey, Marina, Colby, Donn J, Dawson, Liza, Dong, Krista L, Dubé, Karine, Eron, Joseph, Frater, John, Gandhi, Rajesh T, Geleziunas, Romas, Goulder, Philip, Hanna, George J, Jefferys, Richard, Johnston, Rowena, Kuritzkes, Daniel, Li, Jonathan Z, Likhitwonnawut, Udom, van Lunzen, Jan, Martinez-Picado, Javier, Miller, Veronica, Montaner, Luis J, Nixon, Douglas F, Palm, David, Pantaleo, Giuseppe, Peay, Holly, Persaud, Deborah, Salzwedel, Jessica, Salzwedel, Karl, Schacker, Timothy, Sheikh, Virginia, Søgaard, Ole S, Spudich, Serena, Stephenson, Kathryn, Sugarman, Jeremy, Taylor, Jeff, Tebas, Pablo, Tiemessen, Caroline T, Tressler, Randall, Weiss, Carol D, Zheng, Lu, Robb, Merlin L, Michael, Nelson L, Mellors, John W, Deeks, Steven G, and Walker, Bruce D

Subjects
Medical Microbiology, Biomedical and Clinical Sciences, Immunology, Sexually Transmitted Infections, Infectious Diseases, Clinical Trials and Supportive Activities, HIV/AIDS, Clinical Research, 6.1 Pharmaceuticals, 6.9 Resources and infrastructure (treatment evaluation), Infection, Anti-Retroviral Agents, HIV Infections, Humans, Sustained Virologic Response, Viral Load, Withholding Treatment, Medical and Health Sciences, Biomedical and clinical sciences, Health sciences
Abstract

Analytical antiretroviral treatment interruption (ATI) is an important feature of HIV research, seeking to achieve sustained viral suppression in the absence of antiretroviral therapy (ART) when the goal is to measure effects of novel therapeutic interventions on time to viral load rebound or altered viral setpoint. Trials with ATIs also intend to determine host, virological, and immunological markers that are predictive of sustained viral control off ART. Although ATI is increasingly incorporated into proof-of-concept trials, no consensus has been reached on strategies to maximise its utility and minimise its risks. In addition, differences in ATI trial designs hinder the ability to compare efficacy and safety of interventions across trials. Therefore, we held a meeting of stakeholders from many interest groups, including scientists, clinicians, ethicists, social scientists, regulators, people living with HIV, and advocacy groups, to discuss the main challenges concerning ATI studies and to formulate recommendations with an emphasis on strategies for risk mitigation and monitoring, ART resumption criteria, and ethical considerations. In this Review, we present the major points of discussion and consensus views achieved with the goal of informing the conduct of ATIs to maximise the knowledge gained and minimise the risk to participants in clinical HIV research.

Published
2019

14. Increased memory B cell potency and breadth after a SARS-CoV-2 mRNA boost

Author

Muecksch, Frauke, Wang, Zijun, Cho, Alice, Gaebler, Christian, Ben Tanfous, Tarek, DaSilva, Justin, Bednarski, Eva, Ramos, Victor, Zong, Shuai, Johnson, Brianna, Raspe, Raphael, Schaefer-Babajew, Dennis, Shimeliovich, Irina, Daga, Mridushi, Yao, Kai-Hui, Schmidt, Fabian, Millard, Katrina G., Turroja, Martina, Jankovic, Mila, Oliveira, Thiago Y., Gazumyan, Anna, Caskey, Marina, Hatziioannou, Theodora, Bieniasz, Paul D., and Nussenzweig, Michel C.

Published
2022
Full Text
View/download PDF

15. Prolonged viral suppression with anti-HIV-1 antibody therapy

Author

Gaebler, Christian, Nogueira, Lilian, Stoffel, Elina, Oliveira, Thiago Y., Breton, Gaëlle, Millard, Katrina G., Turroja, Martina, Butler, Allison, Ramos, Victor, Seaman, Michael S., Reeves, Jacqueline D., Petroupoulos, Christos J., Shimeliovich, Irina, Gazumyan, Anna, Jiang, Caroline S., Jilg, Nikolaus, Scheid, Johannes F., Gandhi, Rajesh, Walker, Bruce D., Sneller, Michael C., Fauci, Anthony, Chun, Tae-Wook, Caskey, Marina, and Nussenzweig, Michel C.

Published
2022
Full Text
View/download PDF

16. Combination anti-HIV antibodies provide sustained virological suppression

Author

Sneller, Michael C., Blazkova, Jana, Justement, J. Shawn, Shi, Victoria, Kennedy, Brooke D., Gittens, Kathleen, Tolstenko, Jekaterina, McCormack, Genevieve, Whitehead, Emily J., Schneck, Rachel F., Proschan, Michael A., Benko, Erika, Kovacs, Colin, Oguz, Cihan, Seaman, Michael S., Caskey, Marina, Nussenzweig, Michel C., Fauci, Anthony S., Moir, Susan, and Chun, Tae-Wook

Published
2022
Full Text
View/download PDF

17. Analysis of memory B cells identifies conserved neutralizing epitopes on the N-terminal domain of variant SARS-Cov-2 spike proteins

Author

Wang, Zijun, Muecksch, Frauke, Cho, Alice, Gaebler, Christian, Hoffmann, Hans-Heinrich, Ramos, Victor, Zong, Shuai, Cipolla, Melissa, Johnson, Briana, Schmidt, Fabian, DaSilva, Justin, Bednarski, Eva, Ben Tanfous, Tarek, Raspe, Raphael, Yao, Kaihui, Lee, Yu E., Chen, Teresia, Turroja, Martina, Milard, Katrina G., Dizon, Juan, Kaczynska, Anna, Gazumyan, Anna, Oliveira, Thiago Y., Rice, Charles M., Caskey, Marina, Bieniasz, Paul D., Hatziioannou, Theodora, Barnes, Christopher O., and Nussenzweig, Michel C.

Published
2022
Full Text
View/download PDF

18. Effect of 3BNC117 and romidepsin on the HIV-1 reservoir in people taking suppressive antiretroviral therapy (ROADMAP): a randomised, open-label, phase 2A trial

Author

Gruell, Henning, Gunst, Jesper D, Cohen, Yehuda Z, Pahus, Marie H, Malin, Jakob J, Platten, Martin, Millard, Katrina G, Tolstrup, Martin, Jones, R Brad, Conce Alberto, Winnifer D, Lorenzi, Julio C C, Oliveira, Thiago Y, Kümmerle, Tim, Suárez, Isabelle, Unson-O'Brien, Cecilia, Nogueira, Lilian, Olesen, Rikke, Østergaard, Lars, Nielsen, Henrik, Lehmann, Clara, Nussenzweig, Michel C, Fätkenheuer, Gerd, Klein, Florian, Caskey, Marina, and Søgaard, Ole S

Published
2022
Full Text
View/download PDF

20. Relationship between intact HIV-1 proviruses in circulating CD4+ T cells and rebound viruses emerging during treatment interruption

Author

Lu, Ching-Lan, Pai, Joy A, Nogueira, Lilian, Mendoza, Pilar, Gruell, Henning, Oliveira, Thiago Y, Barton, John, Lorenzi, Julio CC, Cohen, Yehuda Z, Cohn, Lillian B, Klein, Florian, Caskey, Marina, Nussenzweig, Michel C, and Jankovic, Mila

Subjects
Medical Microbiology, Biomedical and Clinical Sciences, Immunology, HIV/AIDS, Infectious Diseases, Clinical Research, Infection, Anti-HIV Agents, Antibodies, Monoclonal, Humanized, Antibodies, Neutralizing, Broadly Neutralizing Antibodies, CD4-Positive T-Lymphocytes, HIV Antibodies, HIV Infections, HIV-1, Humans, Phylogeny, Proviruses, Virus Latency, Virus Replication, HIV, latent reservoir, sequencing, analytical treatment interruption
Abstract

Combination antiretroviral therapy controls but does not cure HIV-1 infection because a small fraction of cells harbor latent viruses that can produce rebound viremia when therapy is interrupted. The circulating latent virus reservoir has been documented by a variety of methods, most prominently by viral outgrowth assays (VOAs) in which CD4+ T cells are activated to produce virus in vitro, or more recently by amplifying proviral near full-length (NFL) sequences from DNA. Analysis of samples obtained in clinical studies in which individuals underwent analytical treatment interruption (ATI), showed little if any overlap between circulating latent viruses obtained from outgrowth cultures and rebound viruses from plasma. To determine whether intact proviruses amplified from DNA are more closely related to rebound viruses than those obtained from VOAs, we assayed 12 individuals who underwent ATI after infusion of a combination of two monoclonal anti-HIV-1 antibodies. A total of 435 intact proviruses obtained by NFL sequencing were compared with 650 latent viruses from VOAs and 246 plasma rebound viruses. Although, intact NFL and outgrowth culture sequences showed similar levels of stability and diversity with 39% overlap, the size of the reservoir estimated from NFL sequencing was larger than and did not correlate with VOAs. Finally, intact proviruses documented by NFL sequencing showed no sequence overlap with rebound viruses; however, they appear to contribute to recombinant viruses found in plasma during rebound.

Published
2018

21. Relationship between latent and rebound viruses in a clinical trial of anti–HIV-1 antibody 3BNC117

Author

Cohen, Yehuda Z, Lorenzi, Julio CC, Krassnig, Lisa, Barton, John P, Burke, Leah, Pai, Joy, Lu, Ching-Lan, Mendoza, Pilar, Oliveira, Thiago Y, Sleckman, Christopher, Millard, Katrina, Butler, Allison L, Dizon, Juan P, Belblidia, Shiraz A, Witmer-Pack, Maggi, Shimeliovich, Irina, Gulick, Roy M, Seaman, Michael S, Jankovic, Mila, Caskey, Marina, and Nussenzweig, Michel C

Subjects
Medical Microbiology, Biomedical and Clinical Sciences, Immunology, Clinical Research, HIV/AIDS, Infection, Good Health and Well Being, Adolescent, Adult, Aged, Anti-Retroviral Agents, Female, Follow-Up Studies, HIV Antibodies, HIV Infections, HIV-1, Humans, Male, Middle Aged, Recombination, Genetic, Viral Load, Medical and Health Sciences, Biomedical and clinical sciences, Health sciences
Abstract

A clinical trial was performed to evaluate 3BNC117, a potent anti-HIV-1 antibody, in infected individuals during suppressive antiretroviral therapy and subsequent analytical treatment interruption (ATI). The circulating reservoir was evaluated by quantitative and qualitative viral outgrowth assay (Q2VOA) at entry and after 6 mo. There were no significant quantitative changes in the size of the reservoir before ATI, and the composition of circulating reservoir clones varied in a manner that did not correlate with 3BNC117 sensitivity. 3BNC117 binding site amino acid variants found in rebound viruses preexisted in the latent reservoir. However, only 3 of 217 rebound viruses were identical to 868 latent viruses isolated by Q2VOA and near full-length sequencing. Instead, 63% of the rebound viruses appeared to be recombinants, even in individuals with 3BNC117-resistant reservoir viruses. In conclusion, viruses emerging during ATI in individuals treated with 3BNC117 are not the dominant species found in the circulating latent reservoir, but frequently appear to represent recombinants of latent viruses.

Published
2018

22. The RIO trial: rationale, design, and the role of community involvement in a randomised placebo-controlled trial of antiretroviral therapy plus dual long-acting HIV-specific broadly neutralising antibodies (bNAbs) in participants diagnosed with recent HIV infection—study protocol for a two-stage randomised phase II trial

Author

Lee, Ming Jie, Collins, Simon, Babalis, Daphne, Johnson, Nicholas, Falaschetti, Emanuela, Prevost, A. Toby, Ashraf, Ambreen, Jacob, Milaana, Cole, Tom, Hurley, Lisa, Pace, Matthew, Ogbe, Ane, Khan, Maryam, Zacharopoulou, Panagiota, Brown, Helen, Sutherland, Euan, Box, Hanna, Fox, Julie, Deeks, Steven, Horowitz, Jill, Nussenzweig, Michel C., Caskey, Marina, Frater, John, and Fidler, Sarah

Published
2022
Full Text
View/download PDF

23. Administration of broadly neutralizing anti-HIV-1 antibodies at ART initiation maintains long-term CD8+ T cell immunity

Author

Rosás-Umbert, Miriam, Gunst, Jesper D., Pahus, Marie H., Olesen, Rikke, Schleimann, Mariane, Denton, Paul W., Ramos, Victor, Ward, Adam, Kinloch, Natalie N., Copertino, Dennis C., Escribà, Tuixent, Llano, Anuska, Brumme, Zabrina L., Brad Jones, R., Mothe, Beatriz, Brander, Christian, Fox, Julie, Nussenzweig, Michel C., Fidler, Sarah, Caskey, Marina, Tolstrup, Martin, and Søgaard, Ole S.

Published
2022
Full Text
View/download PDF

24. SARS CoV-2 mRNA vaccination exposes latent HIV to Nef-specific CD8+ T-cells

Author

Stevenson, Eva M., Terry, Sandra, Copertino, Dennis, Leyre, Louise, Danesh, Ali, Weiler, Jared, Ward, Adam R., Khadka, Pragya, McNeil, Evan, Bernard, Kevin, Miller, Itzayana G., Ellsworth, Grant B., Johnston, Carrie D., Finkelsztein, Eli J., Zumbo, Paul, Betel, Doron, Dündar, Friederike, Duncan, Maggie C., Lapointe, Hope R., Speckmaier, Sarah, Moran-Garcia, Nadia, Papa, Michelle Premazzi, Nicholes, Samuel, Stover, Carissa J., Lynch, Rebecca M., Caskey, Marina, Gaebler, Christian, Chun, Tae-Wook, Bosque, Alberto, Wilkin, Timothy J., Lee, Guinevere Q., Brumme, Zabrina L., and Jones, R. Brad

Published
2022
Full Text
View/download PDF

25. High genetic barrier to SARS-CoV-2 polyclonal neutralizing antibody escape

Author

Schmidt, Fabian, Weisblum, Yiska, Rutkowska, Magdalena, Poston, Daniel, DaSilva, Justin, Zhang, Fengwen, Bednarski, Eva, Cho, Alice, Schaefer-Babajew, Dennis J., Gaebler, Christian, Caskey, Marina, Nussenzweig, Michel C., Hatziioannou, Theodora, and Bieniasz, Paul D.

Subjects
Viral antibodies -- Genetic aspects, Antibodies -- Genetic aspects, Environmental issues, Science and technology, Zoology and wildlife conservation
Abstract

The number and variability of the neutralizing epitopes targeted by polyclonal antibodies in individuals who are SARS-CoV-2 convalescent and vaccinated are key determinants of neutralization breadth and the genetic barrier to viral escape.sup.1-4. Using HIV-1 pseudotypes and plasma selection experiments with vesicular stomatitis virus/SARS-CoV-2 chimaeras.sup.5, here we show that multiple neutralizing epitopes, within and outside the receptor-binding domain, are variably targeted by human polyclonal antibodies. Antibody targets coincide with spike sequences that are enriched for diversity in natural SARS-CoV-2 populations. By combining plasma-selected spike substitutions, we generated synthetic 'polymutant' spike protein pseudotypes that resisted polyclonal antibody neutralization to a similar degree as circulating variants of concern. By aggregating variant of concern-associated and antibody-selected spike substitutions into a single polymutant spike protein, we show that 20 naturally occurring mutations in the SARS-CoV-2 spike protein are sufficient to generate pseudotypes with near-complete resistance to the polyclonal neutralizing antibodies generated by individuals who are convalescent or recipients who received an mRNA vaccine. However, plasma from individuals who had been infected and subsequently received mRNA vaccination neutralized pseudotypes bearing this highly resistant SARS-CoV-2 polymutant spike, or diverse sarbecovirus spike proteins. Thus, optimally elicited human polyclonal antibodies against SARS-CoV-2 should be resilient to substantial future SARS-CoV-2 variation and may confer protection against potential future sarbecovirus pandemics. A complex range of mutations within the SARS-CoV-2 spike protein is needed to escape polyclonal plasma neutralizing antibodies, and plasma from individuals who were first infected then vaccinated display the greatest resilience to escape mutations., Author(s): Fabian Schmidt [sup.1] , Yiska Weisblum [sup.1] , Magdalena Rutkowska [sup.2] , Daniel Poston [sup.1] , Justin DaSilva [sup.1] , Fengwen Zhang [sup.1] , Eva Bednarski [sup.1] , Alice [...]

Published
2021
Full Text
View/download PDF

26. Anti-SARS-CoV-2 receptor-binding domain antibody evolution after mRNA vaccination

Author

Cho, Alice, Muecksch, Frauke, Schaefer-Babajew, Dennis, Wang, Zijun, Finkin, Shlomo, Gaebler, Christian, Ramos, Victor, Cipolla, Melissa, Mendoza, Pilar, Agudelo, Marianna, Bednarski, Eva, DaSilva, Justin, Shimeliovich, Irina, Dizon, Juan, Daga, Mridushi, Millard, Katrina G., Turroja, Martina, Schmidt, Fabian, Zhang, Fengwen, Tanfous, Tarek Ben, Jankovic, Mila, Oliveria, Thiago Y., Gazumyan, Anna, Caskey, Marina, Bieniasz, Paul D., Hatziioannou, Theodora, and Nussenzweig, Michel C.

Published
2021
Full Text
View/download PDF

27. Affinity maturation of SARS-CoV-2 neutralizing antibodies confers potency, breadth, and resilience to viral escape mutations

Author

Muecksch, Frauke, Weisblum, Yiska, Barnes, Christopher O., Schmidt, Fabian, Schaefer-Babajew, Dennis, Wang, Zijun, C. Lorenzi, Julio C., Flyak, Andrew I., DeLaitsch, Andrew T., Huey-Tubman, Kathryn E., Hou, Shurong, Schiffer, Celia A., Gaebler, Christian, Da Silva, Justin, Poston, Daniel, Finkin, Shlomo, Cho, Alice, Cipolla, Melissa, Oliveira, Thiago Y., Millard, Katrina G., Ramos, Victor, Gazumyan, Anna, Rutkowska, Magdalena, Caskey, Marina, Nussenzweig, Michel C., Bjorkman, Pamela J., Hatziioannou, Theodora, and Bieniasz, Paul D.

Published
2021
Full Text
View/download PDF

28. Recurrent Potent Human Neutralizing Antibodies to Zika Virus in Brazil and Mexico

Author

Robbiani, Davide F, Bozzacco, Leonia, Keeffe, Jennifer R, Khouri, Ricardo, Olsen, Priscilla C, Gazumyan, Anna, Schaefer-Babajew, Dennis, Avila-Rios, Santiago, Nogueira, Lilian, Patel, Roshni, Azzopardi, Stephanie A, Uhl, Lion FK, Saeed, Mohsan, Sevilla-Reyes, Edgar E, Agudelo, Marianna, Yao, Kai-Hui, Golijanin, Jovana, Gristick, Harry B, Lee, Yu E, Hurley, Arlene, Caskey, Marina, Pai, Joy, Oliveira, Thiago, Wunder, Elsio A, Sacramento, Gielson, Nery, Nivison, Orge, Cibele, Costa, Federico, Reis, Mitermayer G, Thomas, Neena M, Eisenreich, Thomas, Weinberger, Daniel M, de Almeida, Antonio RP, West, Anthony P, Rice, Charles M, Bjorkman, Pamela J, Reyes-Teran, Gustavo, Ko, Albert I, MacDonald, Margaret R, and Nussenzweig, Michel C

Subjects
Medical Microbiology, Biomedical and Clinical Sciences, Immunology, Vector-Borne Diseases, Immunization, Vaccine Related, Prevention, Aetiology, 2.1 Biological and endogenous factors, Good Health and Well Being, Animals, Antibodies, Neutralizing, Antibodies, Viral, B-Lymphocytes, Brazil, Female, Humans, Immunologic Memory, Leukocytes, Mononuclear, Male, Mexico, Mice, Zika Virus Infection, Zika virus, antibodies, dengue virus, flavivirus, structure, vaccine, Biological Sciences, Medical and Health Sciences, Developmental Biology, Biological sciences, Biomedical and clinical sciences
Abstract

Antibodies to Zika virus (ZIKV) can be protective. To examine the antibody response in individuals who develop high titers of anti-ZIKV antibodies, we screened cohorts in Brazil and Mexico for ZIKV envelope domain III (ZEDIII) binding and neutralization. We find that serologic reactivity to dengue 1 virus (DENV1) EDIII before ZIKV exposure is associated with increased ZIKV neutralizing titers after exposure. Antibody cloning shows that donors with high ZIKV neutralizing antibody titers have expanded clones of memory B cells that express the same immunoglobulin VH3-23/VK1-5 genes. These recurring antibodies cross-react with DENV1, but not other flaviviruses, neutralize both DENV1 and ZIKV, and protect mice against ZIKV challenge. Structural analyses reveal the mechanism of recognition of the ZEDIII lateral ridge by VH3-23/VK1-5 antibodies. Serologic testing shows that antibodies to this region correlate with serum neutralizing activity to ZIKV. Thus, high neutralizing responses to ZIKV are associated with pre-existing reactivity to DENV1 in humans.

Published
2017

29. A clinical trial of non-invasive imaging with an anti-HIV antibody labelled with copper-64 in people living with HIV and uninfected controls

Author

McMahon, James H., Zerbato, Jennifer M., Lau, Jillian S.Y., Lange, Jaclyn L., Roche, Michael, Tumpach, Carolin, Dantanarayana, Ashanti, Rhodes, Ajantha, Chang, Judy, Rasmussen, Thomas A., Mackenzie, Charlene A., Alt, Karen, Hagenauer, Michelle, Roney, Janine, O'Bryan, Jessica, Carey, Alexandra, McIntyre, Richard, Beech, Paul, O'Keefe, Graeme J., Wichmann, Christian W., Scott, Fiona E., Guo, Nancy, Lee, Sze-Ting, Liu, Zhanqi, Caskey, Marina, Nussenzweig, Michel C., Donnelly, Paul S., Egan, Gary, Hagemeyer, Christoph E., Scott, Andrew M., and Lewin, Sharon R.

Published
2021
Full Text
View/download PDF

30. Safety and pharmacokinetics of intravenous 10-1074 and VRC01LS in young children

Author

Capparelli, Edmund V., Ajibola, Gbolahan, Maswabi, Kenneth, Holme, Molly Pretorius, Bennett, Kara, Powis, Kathleen M., Moyo, Sikhulile, Mohammed, Terence, Maphorisa, Comfort, Hughes, Michael D., Seaton, Kelly E., Tomaras, Georgia D., Mosher, Shad, Taylor, Alison, O’connell, Sarah, Narpala, Sandeep, Mcdermott, Adrian, Caskey, Marina, Gama, Lucio, Lockman, Shahin, Jean-Philippe, Patrick, Makhema, Joseph, Kuritzkes, Daniel R., Lichterfeld, Mathias, and Shapiro, Roger L.

Published
2022
Full Text
View/download PDF

31. Naturally enhanced neutralizing breadth against SARS-CoV-2 one year after infection

Author

Wang, Zijun, Muecksch, Frauke, Schaefer-Babajew, Dennis, Finkin, Shlomo, Viant, Charlotte, Gaebler, Christian, Hoffmann, Hans- Heinrich, Barnes, Christopher O., Cipolla, Melissa, Ramos, Victor, Oliveira, Thiago Y., Cho, Alice, Schmidt, Fabian, Da Silva, Justin, Bednarski, Eva, Aguado, Lauren, Yee, Jim, Daga, Mridushi, Turroja, Martina, Millard, Katrina G., Jankovic, Mila, Gazumyan, Anna, Zhao, Zhen, Rice, Charles M., Bieniasz, Paul D., Caskey, Marina, Hatziioannou, Theodora, and Nussenzweig, Michel C.

Published
2021
Full Text
View/download PDF

32. The impact of analytical treatment interruptions and trial interventions on time to viral re‐suppression in people living with HIV restarting ART in cure‐related clinical studies: a systematic review and meta‐analysis.

Author

Lee, Ming Jie, Eason, Miles, Castagna, Antonella, Laura, Galli, De Scheerder, Marie‐Angelique, Riley, James, Tebas, Pablo, Gunst, Jesper, Søgaard, Ole, Florence, Eric, Kroon, Eugene, De Souza, Mark, Mothe, Beatriz, Caskey, Marina, and Fidler, Sarah

Subjects
STRUCTURED treatment interruption, VIRAL load, INTEGRASE inhibitors, SCIENCE databases, WEB databases
Abstract

Introduction: To assess the effectiveness of novel HIV curative strategies, "cure" trials require periods of closely monitored antiretroviral therapy (ART) analytical treatment interruptions (ATIs). We performed a systematic review and meta‐analysis to identify the impact of ATI with or without novel therapeutics in cure‐related studies on the time to viral re‐suppression following ART restart. Methods: Medline, Embase and Web of Science databases were searched for human studies involving ATIs from 1 January 2015 till 22 April 2024. The primary outcome was time to first viral re‐suppression (plasma HIV viral load [VL] <50 copies/ml) stratified by receipt of interventional drug with ATI (IA) or ATI‐only groups. Random‐effects proportional meta‐analysis and multivariable Cox proportional hazards analysis were performed using R. Results: Of 1073 studies screened, 13 were included that met the inclusion criteria with VL data available after restarting ART (n = 213 participants). There was no difference between time to viral suppression in IA or ATI‐only cohorts (p = 0.22). For 87% of participants, viral suppression within 12 weeks of ART restart was achieved, and all eventually had at least one VL <50 copies/ml during follow‐up. After adjusting for covariables, while participants in the IA cohort were associated with less rapid suppression (adjusted hazard ratio [aHR] 0.61, 95% CI 0.40–0.94, p = 0.026), other factors include greater log VL at ART restart (aHR 0.56, 95% CI 0.46–0.68, p<0.001), duration since HIV diagnosis (aHR 0.93, 95% CI 0.89–0.96) and longer intervals between HIV VL monitoring (aHR 0.66, 95% CI 0.59–0.74, p<0.001). However, the use of integrase inhibitors was associated with more rapid viral suppression (aHR 1.74, 95% CI 1.16–2.59). Discussion: When designing studies involving ATIs, information on time to viral re‐suppression after restarting ART is important to share with participants, and should be regularly monitored and reported, to assess the impact and safety of specific trial interventions in ATI studies. Conclusions: The majority of participants achieved viral suppression after restarting ART in ATI studies. ART regimens containing integrase inhibitors and frequent VL monitoring should be offered for people restarting ART after ATI studies to ensure rapid re‐suppression. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

33. Structures of Human Antibodies Bound to SARS-CoV-2 Spike Reveal Common Epitopes and Recurrent Features of Antibodies

Author

Barnes, Christopher O., West, Anthony P., Jr., Huey-Tubman, Kathryn E., Hoffmann, Magnus A.G., Sharaf, Naima G., Hoffman, Pauline R., Koranda, Nicholas, Gristick, Harry B., Gaebler, Christian, Muecksch, Frauke, Lorenzi, Julio C. Cetrulo, Finkin, Shlomo, Hägglöf, Thomas, Hurley, Arlene, Millard, Katrina G., Weisblum, Yiska, Schmidt, Fabian, Hatziioannou, Theodora, Bieniasz, Paul D., Caskey, Marina, Robbiani, Davide F., Nussenzweig, Michel C., and Bjorkman, Pamela J.

Published
2020
Full Text
View/download PDF

34. A Combination of Human Broadly Neutralizing Antibodies against Hepatitis B Virus HBsAg with Distinct Epitopes Suppresses Escape Mutations

Author

Wang, Qiao, Michailidis, Eleftherios, Yu, Yingpu, Wang, Zijun, Hurley, Arlene M., Oren, Deena A., Mayer, Christian T., Gazumyan, Anna, Liu, Zhenmi, Zhou, Yunjiao, Schoofs, Till, Yao, Kai-hui, Nieke, Jan P., Wu, Jianbo, Jiang, Qingling, Zou, Chenhui, Kabbani, Mohanmmad, Quirk, Corrine, Oliveira, Thiago, Chhosphel, Kalsang, Zhang, Qianqian, Schneider, William M., Jahan, Cyprien, Ying, Tianlei, Horowitz, Jill, Caskey, Marina, Jankovic, Mila, Robbiani, Davide F., Wen, Yumei, de Jong, Ype P., Rice, Charles M., and Nussenzweig, Michel C.

Published
2020
Full Text
View/download PDF

36. mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants

Author

Wang, Zijun, Schmidt, Fabian, Weisblum, Yiska, Muecksch, Frauke, Barnes, Christopher O., Finkin, Shlomo, Schaefer-Babajew, Dennis, Cipolla, Melissa, Gaebler, Christian, Lieberman, Jenna A., Oliveira, Thiago Y., Yang, Zhi, Abernathy, Morgan E., Huey-Tubman, Kathryn E., Hurley, Arlene, Turroja, Martina, West, Kamille A., Gordon, Kristie, Millard, Katrina G., Ramos, Victor, Da Silva, Justin, Xu, Jianliang, Colbert, Robert A., Patel, Roshni, Dizon, Juan, Unson-O’Brien, Cecille, Shimeliovich, Irina, Gazumyan, Anna, Caskey, Marina, Bjorkman, Pamela J., Casellas, Rafael, Hatziioannou, Theodora, Bieniasz, Paul D., and Nussenzweig, Michel C.

Published
2021
Full Text
View/download PDF

37. Evolution of antibody immunity to SARS-CoV-2

Author

Gaebler, Christian, Wang, Zijun, Lorenzi, Julio C. C., Muecksch, Frauke, Finkin, Shlomo, Tokuyama, Minami, Cho, Alice, Jankovic, Mila, Schaefer-Babajew, Dennis, Oliveira, Thiago Y., Cipolla, Melissa, Viant, Charlotte, Barnes, Christopher O., Bram, Yaron, Breton, Gaëlle, Hägglöf, Thomas, Mendoza, Pilar, Hurley, Arlene, Turroja, Martina, Gordon, Kristie, Millard, Katrina G., Ramos, Victor, Schmidt, Fabian, Weisblum, Yiska, Jha, Divya, Tankelevich, Michael, Martinez-Delgado, Gustavo, Yee, Jim, Patel, Roshni, Dizon, Juan, Unson-O’Brien, Cecille, Shimeliovich, Irina, Robbiani, Davide F., Zhao, Zhen, Gazumyan, Anna, Schwartz, Robert E., Hatziioannou, Theodora, Bjorkman, Pamela J., Mehandru, Saurabh, Bieniasz, Paul D., Caskey, Marina, and Nussenzweig, Michel C.

Published
2021
Full Text
View/download PDF

38. Paired quantitative and qualitative assessment of the replication-competent HIV-1 reservoir and comparison with integrated proviral DNA

Author

Lorenzi, Julio CC, Cohen, Yehuda Z, Cohn, Lillian B, Kreider, Edward F, Barton, John P, Learn, Gerald H, Oliveira, Thiago, Lavine, Christy L, Horwitz, Joshua A, Settler, Allison, Jankovic, Mila, Seaman, Michael S, Chakraborty, Arup K, Hahn, Beatrice H, Caskey, Marina, and Nussenzweig, Michel C

Subjects
Medical Microbiology, Biomedical and Clinical Sciences, Immunology, Infectious Diseases, HIV/AIDS, Aetiology, 2.2 Factors relating to the physical environment, Infection, Good Health and Well Being, HIV, reservoir, replication-competent, culture, method
Abstract

HIV-1-infected individuals harbor a latent reservoir of infected CD4+ T cells that is not eradicated by antiretroviral therapy (ART). This reservoir presents the greatest barrier to an HIV-1 cure and has remained difficult to characterize, in part, because the vast majority of integrated sequences are defective and incapable of reactivation. To characterize the replication-competent reservoir, we have combined two techniques, quantitative viral outgrowth and qualitative sequence analysis of clonal outgrowth viruses. Leukapheresis samples from four fully ART-suppressed, chronically infected individuals were assayed at two time points separated by a 4- to 6-mo interval. Overall, 54% of the viruses emerging from the latent reservoir showed gp160 env sequences that were identical to at least one other virus. Moreover, 43% of the env sequences from viruses emerging from the reservoir were part of identical groups at the two time points. Groups of identical expanded sequences made up 54% of proviral DNA, and, as might be expected, the sequences of replication-competent viruses in the active reservoir showed limited overlap with integrated proviral DNA, most of which is known to represent defective viruses. Finally, there was an inverse correlation between proviral DNA clone size and the probability of reactivation, suggesting that replication-competent viruses are less likely to be found among highly expanded provirus-containing cell clones.

Published
2016

39. Convergent antibody responses to SARS-CoV-2 in convalescent individuals

Author

Robbiani, Davide F., Gaebler, Christian, Muecksch, Frauke, Lorenzi, Julio C. C., Wang, Zijun, Cho, Alice, Agudelo, Marianna, Barnes, Christopher O., Gazumyan, Anna, Finkin, Shlomo, Hägglöf, Thomas, Oliveira, Thiago Y., Viant, Charlotte, Hurley, Arlene, Hoffmann, Hans-Heinrich, Millard, Katrina G., Kost, Rhonda G., Cipolla, Melissa, Gordon, Kristie, Bianchini, Filippo, Chen, Spencer T., Ramos, Victor, Patel, Roshni, Dizon, Juan, Shimeliovich, Irina, Mendoza, Pilar, Hartweger, Harald, Nogueira, Lilian, Pack, Maggi, Horowitz, Jill, Schmidt, Fabian, Weisblum, Yiska, Michailidis, Eleftherios, Ashbrook, Alison W., Waltari, Eric, Pak, John E., Huey-Tubman, Kathryn E., Koranda, Nicholas, Hoffman, Pauline R., West, Jr, Anthony P., Rice, Charles M., Hatziioannou, Theodora, Bjorkman, Pamela J., Bieniasz, Paul D., Caskey, Marina, and Nussenzweig, Michel C.

Published
2020
Full Text
View/download PDF

41. Mapping mutations to the SARS-CoV-2 RBD that escape binding by different classes of antibodies

Author

Greaney, Allison J., Starr, Tyler N., Barnes, Christopher O., Weisblum, Yiska, Schmidt, Fabian, Caskey, Marina, Gaebler, Christian, Cho, Alice, Agudelo, Marianna, Finkin, Shlomo, Wang, Zijun, Poston, Daniel, Muecksch, Frauke, Hatziioannou, Theodora, Bieniasz, Paul D., Robbiani, Davide F., Nussenzweig, Michel C., Bjorkman, Pamela J., and Bloom, Jesse D.

Published
2021
Full Text
View/download PDF

42. Detection and characterization of the SARS-CoV-2 lineage B.1.526 in New York

Author

West, Jr., Anthony P., Wertheim, Joel O., Wang, Jade C., Vasylyeva, Tetyana I., Havens, Jennifer L., Chowdhury, Moinuddin A., Gonzalez, Edimarlyn, Fang, Courtney E., Di Lonardo, Steve S., Hughes, Scott, Rakeman, Jennifer L., Lee, Henry H., Barnes, Christopher O., Gnanapragasam, Priyanthi N. P., Yang, Zhi, Gaebler, Christian, Caskey, Marina, Nussenzweig, Michel C., Keeffe, Jennifer R., and Bjorkman, Pamela J.

Published
2021
Full Text
View/download PDF

43. Impact of LS Mutation on Pharmacokinetics of Preventive HIV Broadly Neutralizing Monoclonal Antibodies: A Cross-Protocol Analysis of 16 Clinical Trials in People without HIV.

Author

Mayer, Bryan T., Zhang, Lily, deCamp, Allan C., Yu, Chenchen, Sato, Alicia, Angier, Heather, Seaton, Kelly E., Yates, Nicole, Ledgerwood, Julie E., Mayer, Kenneth, Caskey, Marina, Nussenzweig, Michel, Stephenson, Kathryn, Julg, Boris, Barouch, Dan H., Sobieszczyk, Magdalena E., Edupuganti, Srilatha, Kelley, Colleen F., McElrath, M. Juliana, and Gelderblom, Huub C.

Subjects
MONOCLONAL antibodies, CLINICAL trials, PHARMACOKINETICS, MAXIMUM likelihood statistics, HIV, HIV antibodies
Abstract

Monoclonal antibodies are commonly engineered with an introduction of Met428Leu and Asn434Ser, known as the LS mutation, in the fragment crystallizable region to improve pharmacokinetic profiles. The LS mutation delays antibody clearance by enhancing binding affinity to the neonatal fragment crystallizable receptor found on endothelial cells. To characterize the LS mutation for monoclonal antibodies targeting HIV, we compared pharmacokinetic parameters between parental versus LS variants for five pairs of anti-HIV immunoglobin G1 monoclonal antibodies (VRC01/LS/VRC07-523LS, 3BNC117/LS, PGDM1400/LS PGT121/LS, 10-1074/LS), analyzing data from 16 clinical trials of 583 participants without HIV. We described serum concentrations of these monoclonal antibodies following intravenous or subcutaneous administration by an open two-compartment disposition, with first-order elimination from the central compartment using non-linear mixed effects pharmacokinetic models. We compared estimated pharmacokinetic parameters using the targeted maximum likelihood estimation method, accounting for participant differences. We observed lower clearance rate, central volume, and peripheral volume of distribution for all LS variants compared to parental monoclonal antibodies. LS monoclonal antibodies showed several improvements in pharmacokinetic parameters, including increases in the elimination half-life by 2.7- to 4.1-fold, the dose-normalized area-under-the-curve by 4.1- to 9.5-fold, and the predicted concentration at 4 weeks post-administration by 3.4- to 7.6-fold. Results suggest a favorable pharmacokinetic profile of LS variants regardless of HIV epitope specificity. Insights support lower dosages and/or less frequent dosing of LS variants to achieve similar levels of antibody exposure in future clinical applications. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

44. Safety and antiviral activity of combination HIV-1 broadly neutralizing antibodies in viremic individuals

Author

Bar-On, Yotam, Gruell, Henning, Schoofs, Till, Pai, Joy A., Nogueira, Lilian, Butler, Allison L., Millard, Katrina, Lehmann, Clara, Suárez, Isabelle, Oliveira, Thiago Y., Karagounis, Theodora, Cohen, Yehuda Z., Wyen, Christoph, Scholten, Stefan, Handl, Lisa, Belblidia, Shiraz, Dizon, Juan P., Vehreschild, Jörg J., Witmer-Pack, Maggi, Shimeliovich, Irina, Jain, Kanika, Fiddike, Kerstin, Seaton, Kelly E., Yates, Nicole L., Horowitz, Jill, Gulick, Roy M., Pfeifer, Nico, Tomaras, Georgia D., Seaman, Michael S., Fätkenheuer, Gerd, Caskey, Marina, Klein, Florian, and Nussenzweig, Michel C.

Published
2018
Full Text
View/download PDF

45. Combination therapy with anti-HIV-1 antibodies maintains viral suppression

Author

Mendoza, Pilar, Gruell, Henning, Nogueira, Lilian, Pai, Joy A., Butler, Allison L., Millard, Katrina, Lehmann, Clara, Suárez, Isabelle, Oliveira, Thiago Y., Lorenzi, Julio C. C., Cohen, Yehuda Z., Wyen, Christoph, Kümmerle, Tim, Karagounis, Theodora, Lu, Ching-Lan, Handl, Lisa, Unson-O’Brien, Cecilia, Patel, Roshni, Ruping, Carola, Schlotz, Maike, Witmer-Pack, Maggi, Shimeliovich, Irina, Kremer, Gisela, Thomas, Eleonore, Seaton, Kelly E., Horowitz, Jill, West, Jr, Anthony P., Bjorkman, Pamela J., Tomaras, Georgia D., Gulick, Roy M., Pfeifer, Nico, Fätkenheuer, Gerd, Seaman, Michael S., Klein, Florian, Caskey, Marina, and Nussenzweig, Michel C.

Published
2018
Full Text
View/download PDF

48. Memory B cell development elicited by mRNA booster vaccinations in the elderly

Author

Wang, Zijun, primary, Muecksch, Frauke, additional, Raspe, Raphael, additional, Johannsen, Frederik, additional, Turroja, Martina, additional, Canis, Marie, additional, ElTanbouly, Mohamed A., additional, Santos, Gabriela S. Silva, additional, Johnson, Brianna, additional, Baharani, Viren A., additional, Patejak, Rachel, additional, Yao, Kai-Hui, additional, Chirco, Bennett J., additional, Millard, Katrina G., additional, Shimeliovich, Irina, additional, Gazumyan, Anna, additional, Oliveira, Thiago Y., additional, Bieniasz, Paul D., additional, Hatziioannou, Theodora, additional, Caskey, Marina, additional, and Nussenzweig, Michel C., additional

Published
2023
Full Text
View/download PDF

49. HIV-1 therapy with monoclonal antibody 3BNC117 elicits host immune responses against HIV-1

Author

Schoofs, Till, Klein, Florian, Braunschweig, Malte, Kreider, Edward F., Feldmann, Anna, Nogueira, Lilian, Oliveira, Thiago, Lorenzi, Julio C. C., Parrish, Erica H., Learn, Gerald H., West, Anthony P., Bjorkman, Pamela J., Schlesinger, Sarah J., Seaman, Michael S., Czartoski, Julie, McElrath, M. Juliana, Pfeifer, Nico, Hahn, Beatrice H., Caskey, Marina, and Nussenzweig, Michel C.

Published
2016

Catalog

Books, media, physical & digital resources
See catalog results